Next Article in Journal / Special Issue
Dual Action of the PN159/KLAL/MAP Peptide: Increase of Drug Penetration across Caco-2 Intestinal Barrier Model by Modulation of Tight Junctions and Plasma Membrane Permeability
Previous Article in Journal
Hybrid Nanogels: Stealth and Biocompatible Structures for Drug Delivery Applications
Previous Article in Special Issue
Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update
Article

Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant

1
CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-0504 Coimbra, Portugal
2
Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
3
Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
*
Author to whom correspondence should be addressed.
Received: 22 December 2018 / Revised: 22 January 2019 / Accepted: 4 February 2019 / Published: 9 February 2019
(This article belongs to the Special Issue Transmucosal Absorption Enhancers in the Drug Delivery Field)
Current vaccine research is mostly based on subunit antigens. Despite the better toxicity profile of these antigens they are often poorly immunogenic, so adjuvant association has been explored as a strategy to obtain a potent vaccine formulation. Recently, mast cell activators were recognized as a new class of vaccine adjuvants capable of potentiating mucosal and systemic immune responses. In this study, a co-adjuvanted delivery system was developed and characterized, combining the mast cell activator C48/80 with chitosan nanoparticles (Chi-C48/80 NPs), and the results were compared with plain chitosan nanoparticles. The adsorption of model antigens onto the NP surface as well as the biocompatibility of the system was not affected by the incorporation of C48/80 in the formulation. The stability of the nanoparticles was demonstrated by studying the variation of size and zeta potential at different times, and the ability to be internalized by antigen presenting cells was confirmed by confocal microscopy. Vaccination studies with hepatitis B surface antigen loaded Chi-C48/80 NPs validated the adjuvanticity of the delivery system, demonstrating for the first time a successful association between a mast cell activator and chitosan nanoparticles as a vaccine adjuvant for hepatitis B virus, applied to a nasal vaccination strategy. View Full-Text
Keywords: compound 48/80; chitosan; nanoparticles; mast cell activator; vaccine adjuvant; nasal vaccination compound 48/80; chitosan; nanoparticles; mast cell activator; vaccine adjuvant; nasal vaccination
Show Figures

Figure 1

MDPI and ACS Style

Bento, D.; Jesus, S.; Lebre, F.; Gonçalves, T.; Borges, O. Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant. Pharmaceutics 2019, 11, 72. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics11020072

AMA Style

Bento D, Jesus S, Lebre F, Gonçalves T, Borges O. Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant. Pharmaceutics. 2019; 11(2):72. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics11020072

Chicago/Turabian Style

Bento, Dulce, Sandra Jesus, Filipa Lebre, Teresa Gonçalves, and Olga Borges. 2019. "Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant" Pharmaceutics 11, no. 2: 72. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics11020072

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop